Literature DB >> 19414400

Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-Bromopyruvate on nude mice.

Xiaodong Zhang1, Emilie Varin, Mélanie Briand, Stéphane Allouche, Natacha Heutte, Laurent Schwartz, Laurent Poulain, Philippe Icard.   

Abstract

BACKGROUND: Most cancer cells exhibit increased anaerobic glycolysis and use this metabolic pathway for the generation of ATP as a main source of energy. This impaired metabolism of glucose, leading to the secretion of lactic acid even in the presence of oxygen, is named the Warburg effect. Because cancer cells are partly or mainly dependent on such a pathway to generate ATP, inhibition of glycolysis may slow down the proliferation or kill cells.
MATERIALS AND METHODS: The effect of 3-Bromopyruvate (3-BrPA) alone or associated to cisplatin on nude mice presenting intraperitoneal carcinomatosis developed after intraperitoneal injection of human mesothelioma cells (MSTO-211H) was investigated.
RESULTS: 3-BrPA significantly prolonged survival of animals. Combined with cisplatin, it demonstrated significant benefit on survival whereas cisplatin alone had no or a mild effect.
CONCLUSION: 3-BrPA may thus constitute an interesting novel anticancer drug that could be tested in humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414400

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.

Authors:  Alejandro G Levy; Peter E Zage; Lauren J Akers; Maurizio L Ghisoli; Zhao Chen; Wendy Fang; Sankaranarayanan Kannan; Timothy Graham; Lizhi Zeng; Anna R Franklin; Peng Huang; Patrick A Zweidler-McKay
Journal:  Invest New Drugs       Date:  2010-10-05       Impact factor: 3.850

Review 2.  Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism.

Authors:  Ayelet Erez; Oleg A Shchelochkov; Sharon E Plon; Fernando Scaglia; Brendan Lee
Journal:  Am J Hum Genet       Date:  2011-04-08       Impact factor: 11.025

3.  Experimental results using 3-bromopyruvate in mesothelioma: in vitro and in vivo studies.

Authors:  Philippe Icard; Icard Philippe; Xiao-Dong Zhang; Zhang Xiao-Dong; Edwige Lemoisson; Lemoisson Edwige; Marie-Hélène Louis; Louis Marie-Hélène; Stéphane Allouche; Allouche Stéphane; Hubert Lincet; Lincet Hubert; Laurent Poulain; Poulain Laurent
Journal:  J Bioenerg Biomembr       Date:  2012-02-10       Impact factor: 2.945

4.  Effect of methyl jasmonate and 3-bromopyruvate combination therapy on mice bearing the 4 T1 breast cancer cell line.

Authors:  Somayeh Yousefi; Parisa Darvishi; Zeynab Yousefi; Ali Akbar Pourfathollah
Journal:  J Bioenerg Biomembr       Date:  2020-01-20       Impact factor: 2.945

5.  A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.

Authors:  Jenette Creaney; Ian M Dick; Justine S Leon; Bruce W S Robinson
Journal:  Cancer Genomics Proteomics       Date:  2017 Mar-Apr       Impact factor: 4.069

Review 6.  The metabolic advantage of tumor cells.

Authors:  Maurice Israël; Laurent Schwartz
Journal:  Mol Cancer       Date:  2011-06-07       Impact factor: 27.401

7.  Mechanisms underlying 3-bromopyruvate-induced cell death in colon cancer.

Authors:  Yiming Sun; Zhe Liu; Xue Zou; Yadong Lan; Xiaojin Sun; Xiu Wang; Surong Zhao; Chenchen Jiang; Hao Liu
Journal:  J Bioenerg Biomembr       Date:  2015-06-09       Impact factor: 2.945

8.  Systemic administration of 3-bromopyruvate reveals its interaction with serum proteins in a rat model.

Authors:  Rani Kunjithapatham; Jean-Francois H Geschwind; Pramod P Rao; Tatiana N Boronina; Robert N Cole; Shanmugasundaram Ganapathy-Kanniappan
Journal:  BMC Res Notes       Date:  2013-07-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.